



अखिल भारतीय आयुर्विज्ञान संस्थान राजकोट, गुजरात 360006
All India Institute of Medical Sciences, Rajkot, Gujarat 360006
Institute of National Importance under PMSSY, MoHFW
Government of India www.aiimsrajkot.edu.in

Application Form for Clinical Trials

Title of study:

Principal Investigator (Name, Designation and Affiliation):

1. Type of clinical trial Regulatory trial Academic trial
CTR registration number: NABH accreditation number:.....

2. If regulatory trial, provide status of CDSCO permission letter
Approved and letter attached Applied, under process
Not applied (State reason)

3. Tick all categories that apply to your trial

Phase - I	<input type="checkbox"/>	Phase II	<input type="checkbox"/>
Phase III	<input type="checkbox"/>	Phase IV or Post Marketing Surveillance	<input type="checkbox"/>
Investigational medicinal products	<input type="checkbox"/>	Investigational New drug	<input type="checkbox"/>
Medical devices	<input type="checkbox"/>	New innovative procedure	<input type="checkbox"/>
Drug/device combination	<input type="checkbox"/>	Bioavailability/Bioequivalence studies	<input type="checkbox"/>
Non-drug intervention	<input type="checkbox"/>	Repurposing an existing intervention	<input type="checkbox"/>
Indian system of medicine (AYUSH)	<input type="checkbox"/>	Others (specify)	<input type="checkbox"/>

4. Trial design of the study

I. Randomized	<input type="checkbox"/>	Factorial	<input type="checkbox"/>
Non randomized	<input type="checkbox"/>	Stratified	<input type="checkbox"/>
Parallel	<input type="checkbox"/>	Adaptive	<input type="checkbox"/>
Cross-over	<input type="checkbox"/>	Comparison trial	<input type="checkbox"/>
Cluster	<input type="checkbox"/>	Superiority trial	<input type="checkbox"/>
Matched-pair	<input type="checkbox"/>	Non-inferiority trial	<input type="checkbox"/>
Others (<i>specify</i>)	<input type="checkbox"/>	Equivalence trial	<input type="checkbox"/>

II. If there is randomization, how will the participants be allocated to the control and study group(s)?
.....
.....

III. Describe the method of allocation concealment (blinding / masking), if applicable.
.....

5. List the primary / secondary outcomes of the trial.

.....
.....

6. Is there a Contract Research Organization (CRO) /Site Management Organisation (SMO) / Any other agency such as public relation/human resource? Yes No

If yes, Name and Contact details:

.....
.....

State how the CRO/SMO/agency will be involved in the conduct of the trial (tick all that apply)

- | | | | |
|------------------------|--------------------------|--|--------------------------|
| Project management | <input type="checkbox"/> | Clinical and medical monitoring | <input type="checkbox"/> |
| Regulatory affairs | <input type="checkbox"/> | Data management | <input type="checkbox"/> |
| Statistical support | <input type="checkbox"/> | Medical writing | <input type="checkbox"/> |
| Site management | <input type="checkbox"/> | Audits, quality control, quality assurance | <input type="checkbox"/> |
| Finance management | <input type="checkbox"/> | Recruitment and training | <input type="checkbox"/> |
| Administrative support | <input type="checkbox"/> | Others (<i>specify</i>) | <input type="checkbox"/> |

7. Please provide the following details about the intervention being used in the protocol

I. Drug/s, device/s and/or biologics; if yes, provide regulatory approval details. Yes No NA

.....
.....

II. Already approved drugs or a combination of two or more drugs with new indications / change in dosage form / route of administration. If yes, provide details. Yes No NA

.....
.....

III. Provide contact details of who prepared and /or is manufacturing the drug/s, device/s and biologics.

.....
.....

IV. Provide details of patent of the drug/s, device/s and biologics.

.....
.....

8. Describe in brief any preparatory work or site preparedness for the protocol? Yes No NA

If yes, (100words).....

.....
.....
.....
.....

9. Is there an initial screening/ use of existing database for participant selection? Yes No NA

If Yes, provide details¹.....
.....
.....
.....

10. Provide details of anticipated incidence, frequency and duration of adverse events related to the intervention.
If yes, what are the arrangements made to address them ? Yes No NA

.....
.....
.....

11. Justify the use of the placebo and risks entailed to participants. Yes No NA

.....
.....
.....

12. Will current standard of care be provided to the control arm in the study? Yes No NA

If no, please justify.
.....
.....
.....

13. Justify any plans to withdraw standard therapy during the study. Yes No NA

.....
.....
.....

14. Describe the rules to stop the protocol in case of any adverse events. Yes No NA

.....
.....
.....
.....

15. Provide details of Data and Safety Monitoring Plan. Yes No

.....
.....
.....

¹ In order to select participants for your protocol does the protocol require you to screen an initial population or refer to an existing database before shortlisting participants. If yes, provide details on the same

16. Participant Information Sheet(PIS) and Informed Consent Form (ICF)

English

Other(*Specify*)

.....
.....

List the languages in which translations were done

.....

Justify if translation not done

.....

17. Involvement/consultation of statistician in the study design Yes No NA

18. Provide details of insurance coverage of trial Yes No

.....
.....

I. Medical Council of India (MCI) or the State Medical Council registration details of Principal Investigator

Yes No

.....
.....

II. GCP training in last 3 years by investigators. Please enclose PI certificate Yes No

Signature of PI:

dd	mm	yy
----	----	----